OPC-131461
/ Otsuka
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
January 28, 2025
A Proof-of-concept Trial for OPC 131461 in Patients Hospitalized for Worsening Heart Failure
(clinicaltrials.gov)
- P2 | N=264 | Not yet recruiting | Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
New P2 trial • Cardiovascular • Congestive Heart Failure • Heart Failure
October 31, 2024
A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])
(clinicaltrials.gov)
- P2 | N=157 | Completed | Sponsor: Otsuka Pharmaceutical Co., Ltd. | Recruiting ➔ Completed
Trial completion • Cardiovascular • Congestive Heart Failure • Heart Failure
January 30, 2024
A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])
(clinicaltrials.gov)
- P2 | N=155 | Recruiting | Sponsor: Otsuka Pharmaceutical Co., Ltd. | Trial completion date: Mar 2024 ➔ Sep 2024 | Trial primary completion date: Mar 2024 ➔ Sep 2024
Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure
November 14, 2022
A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])
(clinicaltrials.gov)
- P2 | N=155 | Recruiting | Sponsor: Otsuka Pharmaceutical Co., Ltd.
New P2 trial • Cardiovascular • Congestive Heart Failure • Heart Failure
1 to 4
Of
4
Go to page
1